Galapagos N.V. - Asset Resilience Ratio

Latest as of March 2026: 86.45%

Galapagos N.V. (GLPG) has an Asset Resilience Ratio of 86.45% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€2.92 Billion

≈ $3.41 Billion USD Cash + Short-term Investments

Total Assets

€3.37 Billion

≈ $3.94 Billion USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2014–2025)

This chart shows how Galapagos N.V.'s Asset Resilience Ratio has changed over time. Check Galapagos N.V. (GLPG) strategic asset index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Galapagos N.V.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see GLPG company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€2.92 Billion	86.45%
Total Liquid Assets	€2.92 Billion	86.45%

Asset Resilience Insights

Very High Liquidity: Galapagos N.V. maintains exceptional liquid asset reserves at 86.45% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Galapagos N.V. Industry Peers by Asset Resilience Ratio

Compare Galapagos N.V.'s asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	0.05%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Syndax Pharmaceuticals Inc NASDAQ:SNDX	Biotechnology	46.79%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Vor Biopharma Inc NASDAQ:VOR	Biotechnology	63.47%
Chengdu Kanghua Biological Products SHE:300841	Biotechnology	1.19%
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	Biotechnology	4.35%

Annual Asset Resilience Ratio for Galapagos N.V. (2014–2025)

The table below shows the annual Asset Resilience Ratio data for Galapagos N.V..

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	85.43%	€2.91 Billion ≈ $3.40 Billion	€3.41 Billion ≈ $3.98 Billion	+11.60pp
2024-12-31	73.83%	€3.05 Billion ≈ $3.57 Billion	€4.14 Billion ≈ $4.84 Billion	-6.90pp
2023-12-31	80.73%	€3.52 Billion ≈ $4.11 Billion	€4.36 Billion ≈ $5.09 Billion	+4.99pp
2022-12-31	75.74%	€3.59 Billion ≈ $4.19 Billion	€4.73 Billion ≈ $5.53 Billion	+28.18pp
2021-12-31	47.56%	€2.47 Billion ≈ $2.89 Billion	€5.19 Billion ≈ $6.07 Billion	-5.37pp
2020-12-31	52.93%	€3.03 Billion ≈ $3.54 Billion	€5.72 Billion ≈ $6.68 Billion	-11.65pp
2019-12-31	64.58%	€3.92 Billion ≈ $4.58 Billion	€6.07 Billion ≈ $7.09 Billion	+63.98pp
2016-12-31	0.61%	€6.57 Million ≈ $7.68 Million	€1.08 Billion ≈ $1.27 Billion	-0.94pp
2015-12-31	1.55%	€6.86 Million ≈ $8.02 Million	€442.51 Million ≈ $517.35 Million	-2.30pp
2014-12-31	3.85%	€10.42 Million ≈ $12.18 Million	€270.47 Million ≈ $316.20 Million	--

pp = percentage points

About Galapagos N.V.

AS:GLPG Netherlands Biotechnology

Market Cap

$2.07 Billion

€1.77 Billion EUR

Market Cap Rank

#6981 Global

#48 in Netherlands

Share Price

€26.90

Change (1 day)

+4.67%

52-Week Range

€23.40 - €31.84

All Time High

€249.50